David A Bellnier
Overview
Explore the profile of David A Bellnier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
576
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ivanick N, Oakley E, Kunadharaju R, Brackett C, Bellnier D, Tworek L, et al.
JTO Clin Res Rep
. 2022 Oct;
3(10):100372.
PMID: 36188632
Objective: Patients with inoperable extrabronchial or endobronchial tumors who are not candidates for curative radiotherapy have dire prognoses with no effective long-term treatment options. To reveal that our computer-optimized interstitial...
2.
Shafirstein G, Oakley E, Hamilton S, Habitzruther M, Chamberlain S, Sexton S, et al.
Methods Mol Biol
. 2022 May;
2451:151-162.
PMID: 35505016
Interstitial photodynamic therapy (I-PDT) is a promising therapy considered for patients with locally advanced cancer. In I-PDT, laser fibers are inserted into the tumor for effective illumination and activation of...
3.
Shafirstein G, Bellnier D, Oakley E, Hamilton S, Habitzruther M, Tworek L, et al.
Br J Cancer
. 2018 Oct;
119(10):1191-1199.
PMID: 30353043
Background: Currently delivered light dose (J/cm) is the principal parameter guiding interstitial photodynamic therapy (I-PDT) of refractory locally advanced cancer. The aim of this study was to investigate the impact...
4.
Oakley E, Bellnier D, Hutson A, Wrazen B, Arshad H, Quon H, et al.
Lasers Surg Med
. 2017 Feb;
49(6):599-608.
PMID: 28185275
Background And Objectives: Image-based treatment planning can be used to compute the delivered light dose during interstitial photodynamic therapy (I-PDT) of locally advanced head and neck squamous cell carcinoma (LA-HNSCC)....
5.
Sajisevi M, Rigual N, Bellnier D, Seshadri M
J Oral Maxillofac Surg Med Pathol
. 2015 Mar;
27(2):159-165.
PMID: 25750858
Objective: Photodynamic therapy (PDT) is a clinically approved minimally invasive treatment for cancer. In this preclinical study, using an imaging-guided approach, we examined the potential utility of PDT in the...
6.
Shafirstein G, Rigual N, Arshad H, Cooper M, Bellnier D, Wilding G, et al.
Head Neck
. 2015 Jan;
38 Suppl 1:E377-83.
PMID: 25580824
Background: The purpose of this study was for us to report results regarding the safety of 3-(1'-hexyloxyethyl) pyropheophorbide-a (HPPH) mediated photodynamic therapy (PDT) in early laryngeal disease, and offer preliminary...
7.
Oakley E, Wrazen B, Bellnier D, Syed Y, Arshad H, Shafirstein G
Lasers Surg Med
. 2015 Jan;
47(1):60-7.
PMID: 25559426
Background And Objectives: Several clinical studies suggest that interstitial photodynamic therapy (I-PDT) may benefit patients with locally advanced head and neck cancer (LAHNC). For I-PDT, the therapeutic light is delivered...
8.
Zeitouni N, Sunar U, Rohrbach D, Paquette A, Bellnier D, Shi Y, et al.
Dermatol Surg
. 2014 Nov;
40(12):1390-4.
PMID: 25393353
Background: Topical photodynamic therapy (PDT) for selected nonmelanoma skin cancer using 5-aminolevulinic acid (ALA) or methyl aminolevulinate (MAL) has yielded high long-term complete response rates with very good cosmesis. Pain...
9.
Shams M, Owczarczak B, Manderscheid-Kern P, Bellnier D, Gollnick S
Cancer Immunol Immunother
. 2014 Nov;
64(3):287-97.
PMID: 25384911
Effective therapy for advanced cancer often requires treatment of both primary tumors and systemic disease that may not be apparent at initial diagnosis. Numerous studies have shown that stimulation of...
10.
Rigual N, Shafirstein G, Cooper M, Baumann H, Bellnier D, Sunar U, et al.
Clin Cancer Res
. 2013 Oct;
19(23):6605-13.
PMID: 24088736
Purpose: The primary objective was to evaluate safety of 3-(1'-hexyloxyethyl)pyropheophorbide-a (HPPH) photodynamic therapy (HPPH-PDT) for dysplasia and early squamous cell carcinoma of the head and neck (HNSCC). Secondary objectives were...